Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

The US Food and Drug Administration (FDA) has expanded the approved use of Nubeqa (darolutamide) for patients with metastatic castration-sensitive prostate cancer (mCSPC). The drug is now approved for ...

Adding niraparib to AAP and ADT improved rPFS in mCSPC patients with HRR mutations in the phase 3 AMPLITUDE trial.

(HealthDay News) — Acupuncture may reduce nocturia in patients treated for prostate cancer, according to a research letter published in JAMA Oncology.

The number of cancer survivors in the United States reached 18.6 million as of January 1 this year and is projected to exceed 22 million by 2035.

T-DXd plus pertuzumab can improve outcomes when compared to treatment with a taxane, trastuzumab, and pertuzumab in patients with HER2+ advanced breast cancer.

Tarlatamab improved PFS and OS over chemotherapy as second-line treatment in patients with SCLC in the phase 3 DeLLphi-304 trial.

Americans planning to travel outside the country should make sure they’re vaccinated against measles, the CDC says.

Cancer organizations are urging researchers, oncologists, and other stakeholders to advocate for cancer research.

Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high ...